128 related articles for article (PubMed ID: 1446048)
1. Should women with node-negative breast cancer receive adjuvant chemotherapy?--Insights from a decision analysis model.
Hillner BE; Smith TJ
Breast Cancer Res Treat; 1992; 23(1-2):17-27. PubMed ID: 1446048
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
Hillner BE; Smith TJ
N Engl J Med; 1991 Jan; 324(3):160-8. PubMed ID: 1898533
[TBL] [Abstract][Full Text] [Related]
3. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.
Hillner BE; Smith TJ; Desch CE
Breast Cancer Res Treat; 1993; 25(2):97-105. PubMed ID: 8347850
[TBL] [Abstract][Full Text] [Related]
4. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
Desch CE; Hillner BE; Smith TJ; Retchin SM
J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
[TBL] [Abstract][Full Text] [Related]
5. A model of chemotherapy in node-negative breast cancer.
Hillner BE; Smith TJ
J Natl Cancer Inst Monogr; 1992; (11):143-9. PubMed ID: 1627420
[TBL] [Abstract][Full Text] [Related]
6. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
8. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
9. Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?
Alarid-Escudero F; Blaes AH; Kuntz KM
Breast J; 2017 Jul; 23(4):401-409. PubMed ID: 28117517
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.
Chao C; Studts JL; Abell T; Hadley T; Roetzer L; Dineen S; Lorenz D; YoussefAgha A; McMasters KM
J Clin Oncol; 2003 Dec; 21(23):4299-305. PubMed ID: 14581440
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
Hillner BE; Smith TJ; Desch CE
JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
Elkin EB; Weinstein MC; Kuntz KM; Bunnell CA; Weeks JC
Breast Cancer Res Treat; 2005 Sep; 93(1):25-34. PubMed ID: 16184455
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Bonadonna G; Howell A; McArdle CS; Mouridsen HT; Rubens RD; Welvaart K
Cancer J Sci Am; 1995; 1(2):114-21. PubMed ID: 9166464
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
17. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
18. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.
Whelan T; Sawka C; Levine M; Gafni A; Reyno L; Willan A; Julian J; Dent S; Abu-Zahra H; Chouinard E; Tozer R; Pritchard K; Bodendorfer I
J Natl Cancer Inst; 2003 Apr; 95(8):581-7. PubMed ID: 12697850
[TBL] [Abstract][Full Text] [Related]
19. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
20. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
